Ipamorelin peptide is also known as:
- Ipamorelin Acetate
- GRF (1-29) NH2
- MHP-127
- NNC 26-0161
Ipamorelin is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is a growth hormone secretagogue (GHS) peptide, which means that it stimulates the release of growth hormone from the anterior pituitary gland. Ipamorelin is different from other GHS peptides in a few ways. First, it is more selective for the growth hormone-releasing hormone (GHRH) receptor, which means that it is less likely to cause other side effects, such as increased cortisol levels. Second, ipamorelin has a longer half-life, which means that it can be administered less frequently.
Ipamorelin is currently being investigated for the treatment of a variety of conditions, including:
- Growth hormone deficiency
- Muscle wasting
- Osteoporosis
- Diabetes
- Heart disease
- Stroke
- Alzheimer’s disease
Ipamorelin is not yet approved by the US Food and Drug Administration (FDA) for any use. It is considered an investigational drug and is only available through clinical trials.
Other names for ipamorelin peptide
Ipamorelin is sometimes referred to by other names, such as:
- Growth hormone secretagogue (GHS)
- Growth hormone releasing factor (GHRF) analogue
- Ghrelin agonist
These other names reflect the fact that ipamorelin is a synthetic peptide that mimics the effects of the natural hormone ghrelin. Ghrelin is a hormone that is produced in the stomach and intestines. It is known as the “hunger hormone” because it stimulates appetite. Ghrelin also has other effects, such as stimulating the release of growth hormone.
Ipamorelin is a promising new therapy for a variety of conditions. It is important to note that ipamorelin is an investigational drug and is not yet approved by the US Food and Drug Administration (FDA) for any use. More research is needed to determine the long-term safety and efficacy of ipamorelin therapy.
If you are interested in learning more about ipamorelin, talk to your doctor.
